Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?

S J Cleland, B M Fisher, H M Colhoun, N Sattar, J R Petrie, S J Cleland, B M Fisher, H M Colhoun, N Sattar, J R Petrie

Abstract

In this review, we explore the concept of 'double diabetes', a combination of type 1 diabetes with features of insulin resistance and type 2 diabetes. After considering whether double diabetes is a useful concept, we discuss potential mechanisms of increased insulin resistance in type 1 diabetes before examining the extent to which double diabetes might increase the risk of cardiovascular disease (CVD). We then go on to consider the proposal that weight gain from intensive insulin regimens may be associated with increased CV risk factors in some patients with type 1 diabetes, and explore the complex relationships between weight gain, insulin resistance, glycaemic control and CV outcome. Important comparisons and contrasts between type 1 diabetes and type 2 diabetes are highlighted in terms of hepatic fat, fat partitioning and lipid profile, and how these may differ between type 1 diabetic patients with and without double diabetes. In so doing, we hope this work will stimulate much-needed research in this area and an improvement in clinical practice.

Figures

Fig. 1
Fig. 1
Mechanisms potentially contributing to insulin resistance in type 1 diabetes patients with double diabetes. T1DM, type 1 diabetes

References

    1. Teupe B, Bergis K. Epidemiological evidence for “double diabetes”. Lancet. 1991;337:361–362. doi: 10.1016/0140-6736(91)90988-2.
    1. Wilkin TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type 1 as well as type II diabetes. Int J Obes. 2009;33:716–726. doi: 10.1038/ijo.2009.97.
    1. Roglic G, Colhoun HM, Stevens LK, Lemkes HH, Manes C, Fuller JH. Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med. 1998;15:418–426. doi: 10.1002/(SICI)1096-9136(199805)15:5<418::AID-DIA604>;2-P.
    1. Erbey JR, Kuller LH, Becker DJ, Orchard TJ. The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. Diabetes Care. 1998;21:610–614. doi: 10.2337/diacare.21.4.610.
    1. Petrie JR, Pearson ER, Sutherland C. Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiology. Biochem Pharmacol. 2011;81:471–477. doi: 10.1016/j.bcp.2010.11.010.
    1. Williams D, Erbey J, Becker D, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes. 2000;49:626–632. doi: 10.2337/diabetes.49.4.626.
    1. Heptulla RA, Stewart A, Enocksson S, et al. In situ evidence that peripheral insulin resistance in adolescents with poorly controlled type 1 diabetes is associated with impaired suppression of lipolysis: a microdialysis study. Pediatr Res. 2003;53:830–835. doi: 10.1203/01.PDR.0000059552.08913.B7.
    1. Perseghin G, Lattuada G, Danna M, et al. Insulin resistance, intramyocellular lipid content and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab. 2003;285:E1174–E1181.
    1. Perseghin G, Lattuanda G, De Cobelli F, et al. Reduced intrahepatic fat content is associated with increased whole-body lipid oxidation in patients with type 1 diabetes. Diabetologia. 2005;48:2615–2621. doi: 10.1007/s00125-005-0014-5.
    1. Makimattila S, Virkamaki A, Malmstrom R, Urtiainen T, Yki-Jarvinen H. Insulin resistance in type 1 diabetes mellitus: a major role for reduced glucose extraction. J Clin Endocrinol Metab. 1996;81:707–712. doi: 10.1210/jc.81.2.707.
    1. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet. 1993;342:883–887. doi: 10.1016/0140-6736(93)91943-G.
    1. Kacerovsky M, Brehm A, Chmelik M, et al. Impaired insulin stimulation of muscular ATP production in patients with type 1 diabetes. J Intern Med. 2011;269:189–199. doi: 10.1111/j.1365-2796.2010.02298.x.
    1. Nadeau KJ, Regensteiner JG, Bauer TA, et al. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab. 2010;95:513–521. doi: 10.1210/jc.2009-1756.
    1. Maahs DM, Hokanson JE, Wang H, et al. Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance. Diabetes. 2010;59:1771–1779. doi: 10.2337/db09-1626.
    1. Maahs DM, Nadeau K, Snell-Bergeon JK, et al. Association of insulin sensitivity to lipids across the lifespan in people with type 1 diabetes. Diabet Med. 2011;28:148–155. doi: 10.1111/j.1464-5491.2010.03143.x.
    1. Schauer IE, Snell-Bergeon JK, Bergman BC, et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study. Diabetes. 2011;60:306–314. doi: 10.2337/db10-0328.
    1. Orchard TJ, Olson JC, Erbey JR, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes. Diabetes Care. 2003;26:1374–1379. doi: 10.2337/diacare.26.5.1374.
    1. Zgibor JC, Ruppert K, Orchard TJ, et al. Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in type 1 diabetes risk model. Diabetes Res Clin Pract. 2010;88:314–321. doi: 10.1016/j.diabres.2010.02.009.
    1. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care. 2007;30:707–712. doi: 10.2337/dc06-1982.
    1. Chaturvedi N, Sjolie A-K, Porta M, et al. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care. 2001;24:284–289. doi: 10.2337/diacare.24.2.284.
    1. Pambianco G, Costacou T, Orchard TJ. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care. 2007;30:1248–1254. doi: 10.2337/dc06-2053.
    1. Thorn LM, Forsblom C, Waden J, Finnish Diabetic Nephropathy (FinnDiane) Study Group et al. Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2009;32:950–952. doi: 10.2337/dc08-2022.
    1. Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008;371:1927–1935. doi: 10.1016/S0140-6736(08)60602-9.
    1. Nathan DM, Cleary PA, Backlund JY, The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653. doi: 10.1056/NEJMoa052187.
    1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. doi: 10.1056/NEJM199309303291401.
    1. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998;280:140–146. doi: 10.1001/jama.280.2.140.
    1. Purnell JQ, Dev RK, Steffes MW, et al. Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes. 2003;52:2623–2629. doi: 10.2337/diabetes.52.10.2623.
    1. Conway B, Miller RG, Costacou T, et al. Adiposity and mortality in type 1 diabetes. Int J Obes. 2009;33:796–805. doi: 10.1038/ijo.2009.75.
    1. Ferriss JB, Webb D, Chaturvedi N, Fuller JH, Idzior-Walus B, EURODIAB Prospective Complications Group Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure in type 1 diabetes. Diabet Med. 2006;23:557–564. doi: 10.1111/j.1464-5491.2006.01847.x.
    1. Taylor AM, Dunger DB, Grant DB, Preece MA. Somatomedin-C/IGF-1 measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin dependent diabetes compared with puberty matched controls. Diabetes Res. 1988;9:177–181.
    1. Edge JA, Dunger DB, Matthews DR, Gilbert JP, Smith CP. Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab. 1990;71:1356–1362. doi: 10.1210/jcem-71-5-1356.
    1. Norbert S, Konstantinos K, Hans-Ulrich H. Causes and metabolic consequences of fatty liver. Endocr Rev. 2008;29:939–960. doi: 10.1210/er.2008-0009.
    1. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733–749. doi: 10.1007/s00125-003-1111-y.
    1. Savage DB, Semple RK. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol. 2010;21:329–336. doi: 10.1097/MOL.0b013e32833b7782.
    1. Hodson L, Frayn KN. Hepatic fatty acid partitioning. Curr Opin Lipidol. 2011;22:216–224. doi: 10.1097/MOL.0b013e3283462e16.
    1. Christ ER, Carroll PV, Albany E, et al. Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus. Clin Endocrinol. 2001;55:777–787. doi: 10.1046/j.1365-2265.2001.01407.x.
    1. Vethakkan SR, Walters JM, Gooley JL, et al. Normalized NEFA dynamics during an OGTT after islet transplantation. Transplantation. 2012;94:e49–e51. doi: 10.1097/TP.0b013e3182696a39.
    1. Sinha R, Dufour S, Petersen KF, et al. Assessment of skeletal muscle triglyceride content by 1H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes. 2002;51:1022–1027. doi: 10.2337/diabetes.51.4.1022.
    1. Yazici D, Ozben B, Yavuz D, et al. Epicardial adipose thickness in type 1 diabetic patients. Endocrine. 2011;40:250–255. doi: 10.1007/s12020-011-9478-x.
    1. Nikkila EA, Hormila P. Serum lipids and lipoproteins in insulin-treated diabetes: demonstration of increased high density lipoprotein concentrations. Diabetes. 1978;27:1078–1086.
    1. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes. 1992;41:12–17. doi: 10.2337/diabetes.41.1.12.
    1. Colhoun HM, Taskinen MR, Otvos JD, Van Den Berg P, O’Connor J, Van Tol A. Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes. 2002;51:3300–3305. doi: 10.2337/diabetes.51.11.3300.
    1. Guy J, Ogden L, Wadwa RP, et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case–control study. Diabetes Care. 2009;32:416–420. doi: 10.2337/dc08-1775.
    1. Bain SC, Gill GV, Dyer PH, et al. Characteristics of type 1 diabetes of over 50 years duration (the Golden Years Cohort) Diabet Med. 2003;20:808–811. doi: 10.1046/j.1464-5491.2003.01029.x.
    1. Prince CT, Becker DJ, Costacou T, Miller RG, Orchard TJ. Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC) Diabetologia. 2007;50:2280–2288. doi: 10.1007/s00125-007-0797-7.
    1. Taskinen MR. Lipoprotein lipase in diabetes. Diabetes Metabol Rev. 1987;3:551–570. doi: 10.1002/dmr.5610030208.
    1. James RW, Pometta D. Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes. 1990;39:1158–1164. doi: 10.2337/diabetes.39.10.1158.
    1. Caixas A, Perez A, Payes A, et al. Effects of short-acting insulin analog (Insulin Lispro) versus regular insulin on lipid metabolism in insulin-dependent diabetes mellitus. Metabolism. 1998;47:371–376. doi: 10.1016/S0026-0495(98)90045-2.
    1. Sibley SD, Palmer JP, Hirsch IB, Brunzell J. Visceral obesity, hepatic lipase activity, and dyslipidaemia in type 1 diabetes. J Clin Endocrinol Metab. 2003;88:3379–3384. doi: 10.1210/jc.2002-021693.
    1. Ruotolo G, Parlavecchia M, Taskinen MR, et al. Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity. Diabetes Care. 1994;17:6–12. doi: 10.2337/diacare.17.1.6.
    1. Petruzzo P, Badet L, Lefrancois N, et al. Metabolic consequences of pancreatic systemic or portal venous drainage in simultaneous pancreas-kidney transplant recipients. Diabet Med. 2006;23:654–659. doi: 10.1111/j.1464-5491.2006.01891.x.
    1. Frystyk J, Ritzel RA, Maubach J, et al. Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: impact of glucose regulatory hormones and the growth hormone/insulin-like growth factor axis. J Clin Endocrinol Metab. 2008;93:1758–1766. doi: 10.1210/jc.2007-2350.
    1. Nevalainen P, Lahtela JT, Mustonen J, Pasternack A. The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients. Nephrol Dial Transplant. 1997;12:145–150. doi: 10.1093/ndt/12.1.145.
    1. Selam J-L, Kashyap M, Alberti KGMM, et al. Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type 1 diabetes mellitus. Metabolism. 1989;38:908–912. doi: 10.1016/0026-0495(89)90240-0.
    1. Lahtela JT, Mustonen J, Pasternack A. Comparison of intraperitoneal and subcutaneous insulin administration on insulin sensitivity and serum lipids in type 1 diabetic patients on continuous ambulatory peritoneal dialysis. Clin Sci. 1995;88:427–432.
    1. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572–580. doi: 10.1016/S0140-6736(12)60312-2.
    1. Livingstone SJ, Looker HC, Hothersall EJ, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 2012;9:e1001321. doi: 10.1371/journal.pmed.1001321.
    1. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010;53:809–820. doi: 10.1007/s00125-009-1636-9.
    1. REMOVAL:

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere